Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interval of Disease Inactivity in PCV After Aflibercept
NCT04707027Unknown
- Sponsor
- Chiang Mai University
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label trial of aflibercept in polypoidal choroidal vasculopathy (PCV) (2 arms), sponsored by Chiang Mai University. Primary endpoint: Interval of disease activity on color fundus photography or optical coherence tomography. Status: unknown.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT04707027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707027.